These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6879646)

  • 1. Impairment of phenytoin parahydroxylation as a cause of severe intoxication.
    de Wolff FA; Vermeij P; Ferrari MD; Buruma OJ; Breimer DD
    Ther Drug Monit; 1983 Jun; 5(2):213-5. PubMed ID: 6879646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Bertilsson L; Eichelbaum M; Mellström B; Säwe J; Schulz HU; Sjöqvist F
    Life Sci; 1980 Nov; 27(18):1673-7. PubMed ID: 7442467
    [No Abstract]   [Full Text] [Related]  

  • 5. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine.
    Mucklow JC; Caraher MT; Idle JR; Rawlins MD; Sloan T; Smith RL; Wood P
    Br J Clin Pharmacol; 1980 Mar; 9(3):283P. PubMed ID: 7362739
    [No Abstract]   [Full Text] [Related]  

  • 8. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
    Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
    J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin parahydroxylation is not impaired in patients with young-onset Parkinson's disease.
    Peeters EA; Bloem BR; Kuiper MA; Vermeij P; de Wolff FA; Wolters EC; Roos RA; Ferrari MD
    Clin Neurol Neurosurg; 1994 Nov; 96(4):296-9. PubMed ID: 7889690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
    Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
    Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
    Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family.
    Vermeij P; Ferrari MD; Buruma OJ; Veenema H; de Wolff FA
    Clin Pharmacol Ther; 1988 Nov; 44(5):588-93. PubMed ID: 3180640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fate of orally administered [4-14C]phenytoin in two healthy male volunteers.
    Kadar D; Fecycz TD; Kalow W
    Can J Physiol Pharmacol; 1983 Apr; 61(4):403-7. PubMed ID: 6861002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin in the rat and in man.
    Claesen M; Moustafa MA; Adline J; Vandervorst D; Poupaert JH
    Drug Metab Dispos; 1982; 10(6):667-71. PubMed ID: 6130920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenytoin metabolism in the cat after long-term oral administration.
    Hassell TM; Maguire JH; Cooper CG; Johnson PT
    Epilepsia; 1984 Oct; 25(5):556-63. PubMed ID: 6479107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic hydroxylation of debrisoquine.
    Tucker GT; Silas JH; Iyun AO; Lennard MS; Smith AJ
    Lancet; 1977 Oct; 2(8040):718. PubMed ID: 71525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.